" class="no-js "lang="en-US"> National University of Singapore (NUS) - Medtech Alert
Monday, July 06, 2026

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
National University of Singapore (NUS) | Pharmtech Focus

National University of Singapore (NUS)

About National University of Singapore (NUS)

National University of Singapore (NUS)

At NUS, we are shaping the future through our people and our pursuit of new frontiers in knowledge. In a single century, we have become a university of global influence and an Asian thought leader. Our location at the crossroads of Asia informs our mission and gives us a tremendous vantage point to help create opportunities and address the pressing issues facing Singapore, Asia and the world.

At NUS, we believe in education, research and service that change lives.